KYMR Overview
Upcoming Projects (KYMR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KYMR)
-
Discussing Kymera Therapeutics' Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader for potential treatment of IL-4/IL-13-driven allergic diseases
Ticker: KYMR
Executed On: Aug 22, 2025 at 02:30 PM EDT
Expired Projects (KYMR)
-
Exploring Kymera Therapeutics' KT-474: Insights from Phase 2 Trials on IRAK4 Degradation in Inflammatory Diseases
Ticker: KYMR
Execute By: Sep 30, 2024 -
Discussing Kymera Therapeutics’ KT-474 - IRAK4 Dermatology Program
Ticker: KYMR
Execute By: Oct 29, 2021
Upcoming & Overdue Catalysts (KYMR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KYMR)
-
Kymera Therapeutics (KYMR) Announces Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 in targeted protein degradation
Ticker: KYMR
Occurred on: Jun 28, 2021
Strategic Initiatives (KYMR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
